Pola (1.8 mg/kg by an intravenous [IV] infusion every 3 weeks [Q3W]) was approved based on data from a randomized cohort of a phase 1b/2 study (GO29365 [NCT02257567]), in which pola in combination with BR (pola-BR) improved the outcomes of patients with R/R DLBCL compared with BR, and had a tolerable safety profile [9]. The gene discussed is POLA1; the disease is diffuse large B-cell lymphoma.